5 Key Takeaways

• 1

  Correct staging of diabetic retinopathy (DR) is essential for risk assessment and timely referral to specialists.

• 2

  The International Clinical Diabetic Retinopathy (ICDR) staging system categorizes DR into nonproliferative and proliferative types.

• 3

  Severe NPDR patients require close monitoring every 2 to 3 months due to high progression risk to proliferative diabetic retinopathy (PDR).

• 4

  Diabetic macular edema (DME) can occur at any stage of retinopathy and is a leading cause of vision loss in type 2 diabetes.

• 5

  GLP-1 receptor agonists like semaglutide may temporarily worsen retinopathy but do not show long-term detrimental effects on progression.